628 related articles for article (PubMed ID: 24423324)
1. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.
Colao A; Bronstein MD; Freda P; Gu F; Shen CC; Gadelha M; Fleseriu M; van der Lely AJ; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Sheppard M;
J Clin Endocrinol Metab; 2014 Mar; 99(3):791-9. PubMed ID: 24423324
[TBL] [Abstract][Full Text] [Related]
2. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.
Bronstein MD; Fleseriu M; Neggers S; Colao A; Sheppard M; Gu F; Shen CC; Gadelha M; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Freda P;
BMC Endocr Disord; 2016 Apr; 16():16. PubMed ID: 27039081
[TBL] [Abstract][Full Text] [Related]
3. Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.
Sheppard M; Bronstein MD; Freda P; Serri O; De Marinis L; Naves L; Rozhinskaya L; Hermosillo Reséndiz K; Ruffin M; Chen Y; Colao A
Pituitary; 2015 Jun; 18(3):385-94. PubMed ID: 25103549
[TBL] [Abstract][Full Text] [Related]
4. Somatotropinomas inadequately controlled with octreotide may over-respond to pasireotide: the importance of dose adjustment to achieve long-term biochemical control.
Shimon I; Saeger W; Wildemberg LE; Gadelha MR
Hormones (Athens); 2017 Jan; 16(1):84-91. PubMed ID: 28500831
[TBL] [Abstract][Full Text] [Related]
5. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly.
Colao A; Auriemma RS; Pivonello R
Pituitary; 2016 Apr; 19(2):210-21. PubMed ID: 26290466
[TBL] [Abstract][Full Text] [Related]
6. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
[TBL] [Abstract][Full Text] [Related]
7. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.
Amato G; Mazziotti G; Rotondi M; Iorio S; Doga M; Sorvillo F; Manganella G; Di Salle F; Giustina A; Carella C
Clin Endocrinol (Oxf); 2002 Jan; 56(1):65-71. PubMed ID: 11849248
[TBL] [Abstract][Full Text] [Related]
8. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
Colao A; Pivonello R; Rosato F; Tita P; De Menis E; Barreca A; Ferrara R; Mainini F; Arosio M; Lombardi G
Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study.
Shimon I; Adnan Z; Gorshtein A; Baraf L; Saba Khazen N; Gershinsky M; Pauker Y; Abid A; Niven MJ; Shechner C; Greenman Y
Endocrine; 2018 Nov; 62(2):448-455. PubMed ID: 30051198
[TBL] [Abstract][Full Text] [Related]
10. T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly.
Coopmans EC; Schneiders JJ; El-Sayed N; Erler NS; Hofland LJ; van der Lely AJ; Petrossians P; Potorac J; Muhammad A; Neggers SJCMM
Eur J Endocrinol; 2020 Jun; 182(6):595-605. PubMed ID: 32375119
[TBL] [Abstract][Full Text] [Related]
11. Octreotide LAR for the treatment of acromegaly.
Vallette S; Serri O
Expert Opin Drug Metab Toxicol; 2008 Jun; 4(6):783-93. PubMed ID: 18611118
[TBL] [Abstract][Full Text] [Related]
12. Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly.
Schmid HA; Brue T; Colao A; Gadelha MR; Shimon I; Kapur K; Pedroncelli AM; Fleseriu M
Endocrine; 2016 Jul; 53(1):210-9. PubMed ID: 26906713
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study.
Petersenn S; Farrall AJ; De Block C; Melmed S; Schopohl J; Caron P; Cuneo R; Kleinberg D; Colao A; Ruffin M; Hermosillo Reséndiz K; Hughes G; Hu K; Barkan A
Pituitary; 2014 Apr; 17(2):132-40. PubMed ID: 23529827
[TBL] [Abstract][Full Text] [Related]
14. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.
Petersenn S; Schopohl J; Barkan A; Mohideen P; Colao A; Abs R; Buchelt A; Ho YY; Hu K; Farrall AJ; Melmed S; Biller BM;
J Clin Endocrinol Metab; 2010 Jun; 95(6):2781-9. PubMed ID: 20410233
[TBL] [Abstract][Full Text] [Related]
15. Persistent remission of acromegaly in a patient with GH-secreting pituitary adenoma: Effect of treatment with pasireotide long-acting release and consequence of treatment withdrawal.
Yu N; Wang L; Yang H; Pan H; Duan L; Zhu H
J Clin Pharm Ther; 2022 Jun; 47(6):835-840. PubMed ID: 35167717
[TBL] [Abstract][Full Text] [Related]
16. Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly.
Colao A; Auriemma RS; Pivonello R; Kasuki L; Gadelha MR
Pituitary; 2016 Jun; 19(3):235-47. PubMed ID: 26519143
[TBL] [Abstract][Full Text] [Related]
17. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
[TBL] [Abstract][Full Text] [Related]
18. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
[TBL] [Abstract][Full Text] [Related]
19. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly.
Mercado M; Borges F; Bouterfa H; Chang TC; Chervin A; Farrall AJ; Patocs A; Petersenn S; Podoba J; Safari M; Wardlaw J;
Clin Endocrinol (Oxf); 2007 Jun; 66(6):859-68. PubMed ID: 17465997
[TBL] [Abstract][Full Text] [Related]
20. The Effect of 6 Months' Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings.
Witek P; Bolanowski M; Szamotulska K; Wojciechowska-Luźniak A; Jawiarczyk-Przybyłowska A; Kałużny M
Front Endocrinol (Lausanne); 2021; 12():633944. PubMed ID: 33776927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]